First, we examined the recruitment of four coactivators to the PPARα/δ/γ-LBD by synthetic Glaxo–Wellcome (GW) series full agonists and approved PPARα/δ/γ-selective agonists: pemafibrate, seladelpar (approved for the treatment of primary biliary cholangitis in August 2024), and pioglitazone (Figure 1). The gene discussed is PPARA; the disease is biliary liver cirrhosis.